Presentation is loading. Please wait.

Presentation is loading. Please wait.

Dr. François Meyer Director, Healthcare Products and Procedures Assessment Haute Autorité de santé AIFA March 2007 Assessment, Pricing of Pharmaceuticals.

Similar presentations


Presentation on theme: "Dr. François Meyer Director, Healthcare Products and Procedures Assessment Haute Autorité de santé AIFA March 2007 Assessment, Pricing of Pharmaceuticals."— Presentation transcript:

1 Dr. François Meyer Director, Healthcare Products and Procedures Assessment Haute Autorité de santé AIFA March 2007 Assessment, Pricing of Pharmaceuticals in France

2 2 F. Meyer AIFA March 2007 Introducing a New Drug Introducing a new drug in the healthcare system in France : 1 st step: Marketing authorization. - Assessment : CHMP / EMEA / Afssaps - Decision : European Commission / Afssaps 2 nd step: Introduction into national healthcare systems - Assessment: « Health Technology Assessment » Some common principles, many national specificities - Decision: Country specific - France : “Formulary” = Positive list of reimbursed drugs

3 3 F. Meyer AIFA March 2007 European Medicines Agency / Afssaps benefit/risk assessment European Commission /Afssaps : Marketing Authorization Transparency Committee (TC): medical benefit, added value, importance for public health, target population Healthcare Products Economic Committee: agreement / price -volumes Public Price Product Launch Advertising Control -Pharmacovigilance, Risk Management Plans - Observational Studies Periodic Reassessment Haute Autorité de santé Ministre de la santé et de la SS Minister: inscription Nat. Health Insurance Level of co-payment Ag. Française de sécurité sanitaire des produits de santé Medicinal Products in France

4 4 F. Meyer AIFA March 2007 The HAS, new body created in 2005 Board Chair: Prof. L. Degos 7 committees Cabinet Managing director Mr François Romaneix Accredi- tation Guidelines Disease management Healthcare procedures and Products Assessment Information Communi- cation General secreta- riat Practice appraisal CPD Accountancy Network of experts and health professionals throughout France HAS = French National Authority for Health, created 2005

5

6 6 F. Meyer AIFA March 2007 HAS internal assessors HAS Transparency Committee + Health Professionals HAS opinion Review of available data Dossier from Pharma- ceutical Company “ ASSESSMENT ”“ APPRAISAL ” Literature Ministry Economic Committee HTA procedures in France Working Group for Public Health

7 7 F. Meyer AIFA March 2007 Criteria for Drug Appraisal HAS performs medicinal products appraisal according to criteria defined in French regulation cost-effectiveness assessment not part of the « legal » criteria SERVICE MEDICAL RENDU (SMR) = Actual Benefit - « Clinical benefit » severity of the disease clinical effectiveness - « Benefit to Public Health » : Impact on Health Status of the global population, Impact on Healthcare organisation and/or Use of healthcare resources... AMELIORATION DU SMR (ASMR) Improvement in Actual Benefit - Comparison to other existing therapies - 4-level scale: from MAJOR improvement (ASMR I) to minor improvement (ASMR IV) - No improvement over existing therapies : (ASMR V )

8 8 F. Meyer AIFA March 2007 Criteria for Pricing Criteria for drug pricing Pricing : Economic Committee for Healh Products = contract negociating committee. Strong link with appraisal results on added value - no added value (ASMR V) : listed only if they bring some savings to the medial treatment - added value (ASMR I to IV) : Price higher than comparators can be accepted Price/volumes agreement : Target population, as assessed by HAS, is taken into account. Innovative drugs : Price deposit instead of negotiation, faster access and « European » price guaranteed Incremenal progress taken into account : Price deposit open to Drugs with minor improvent of actual benefit. Pharmaco- economic studies: optional, only on a case by case basis

9 9 F. Meyer AIFA March 2007 SMR: Actual Benefit Actual Benefit of Drugs in 2005 and 2006

10 10 F. Meyer AIFA March 2007 ASMR: Improvement in Actual Benefit Improvement in Actual Benefit for Drugs

11 11 F. Meyer AIFA March 2007 From efficacy to effectiveness… Efficacy explanatory trials highly selected populations comparator: often placebo outcomes: clinical, often surrogates, adverse effects  ‘is the therapy effective’ Effectiveness pragmatic trials few exclusions comparator: ‘current (best) practice’ outcomes: patient-focused, down- stream resources  ‘real world added value’ Taylor R.S. Value in Health 2001;4:8-11

12 12 F. Meyer AIFA March 2007 HAS opinions on Drugs Content : Assessment of Actual benefit Assessment of Added value (Improvement in actual benefit) Target Population estimate Advice to Prescribers : place in therapy Limits of currently available data and Request for additionnal data collection Availability www.has-sante.fr Information and communication

13 13 F. Meyer AIFA March 2007 Time from Licensing to Reimbursement Drugs can be made available before Marketing Authorisation - products without MA : ATU, clincical trials - Extension of indications : Temporary coverage (HERCEPTIN) Usual procedure : Time from licensing to listing Time to application submission by Pharmaceutical Company Time of assessment by HAS Time of price negotiation and decision publication Legal limit : Max. 180 days from dossier submission to decision Recent trends Time for issuing HAS opinion reduced Average 2005: 150 days, 2006 100 days 65% in less than 90 days Innovative products : anticipated assessment, opinion issued within one month after licensing Possible access before licensing for innovative products in severe disease

14 14 F. Meyer AIFA March 2007 Some Innovative Drugs DrugMarketing Authorisation Application Submission Improveme nt in Actual Benefit Final Opinion Time to Final Opinion X…neuro 28/07/2005 03/08/2005 III – IV25/10/200583 days T…cancer19/09/200527/10/2005IV – V20/03/2006 98 days K…cancer25/10/200520/12/2005III13/03/2006 83 days N…cancer19/07/200628/07/2006II22/09/200650 days E…metab28/08/200611/09/2006II - III9/10/200627 days

15 15 F. Meyer AIFA March 2007 No of Drugs taken during the previous 7days No of Visits / 12 months No of visits without Drug prescription (out of 100) December 2004, 1000 Patients and 250 GPs per country France Germany Spain Netherlands Drug prescription in France

16 16 F. Meyer AIFA March 2007 www.eunethta.net

17 Thank You

18 18 F. Meyer AIFA March 2007 French Healthcare System in a Nutshell Unitary centralized state NHI Mandatory, coverage for the entire population List of 30 ‘long term conditions’ with 100% coverage - 13% of French population, 60% of expenses Supplementary Health Insurance: 90 percent of the population subscribe to supplementary health insurance to cover other benefits not covered under NHI Pharmaceuticals : Positive list of reimbursed products Supplementary insurance : 100% reimbursement rate for all listed drugs, no money to be paid to pharmacist in most cases Some recent delistings of ‘old’ products

19 19 F. Meyer AIFA March 2007 French System in a Nutshell – Cont. French healthcare organization Ambulatory care : dominated by solo-based, fee-for-service private practice Mix of public and propietary hospitals for acute institutional care Patients free to navigate and be reimbursed under NHI. Pharmaceutical expenditure Percentage of total health care expenditure France > UK > Netherlands > Norway Per capita drug expenditure Highest level in Europe

20 20 F. Meyer AIFA March 2007 Healthcare reform 2004 ‘Health insurance system losing 23,000 € a minute’.. Healthcare reform 2004 “to provide better care while spending less.” creation of HAS, independent scientific body - HTA for drugs, medical devices, procedures - clinical guidelines, DMP for long term conditions - hospital accreditation, practice appraisal, CPD… - improvement in Health Professionals and Public information National Union of Health Insurance Funds (UNCAM) Shared, computerized medical record Treating physician …

21 21 F. Meyer AIFA March 2007 First results, perspectives Results obtained : Antibiotics consumption : longstanding decrease in use Generics: end of the French exception ? Drugs delistings : not welcome but moreless accepted Perspectives Self medication Rational use of pharmaceuticals Improvement in methodology of drugs assessment/appraisal Post marketing monitoring of drugs - safety - clinical and cost effectiveness Risk sharing International cooperation EUnetHTA, Euroscan, HTAi, Nice-Iqwig-HAS cooperation… European Commission


Download ppt "Dr. François Meyer Director, Healthcare Products and Procedures Assessment Haute Autorité de santé AIFA March 2007 Assessment, Pricing of Pharmaceuticals."

Similar presentations


Ads by Google